Status:
UNKNOWN
Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Early-stage Breast Cancer
Eligibility:
FEMALE
50-70 years
Phase:
NA
Brief Summary
Background Worldwide, an increasing number of people are affected by cancer. Breast Cancer is one of the most common cancers worldwide. Patients with early non-metastatic breast cancer are a growing g...
Detailed Description
Background Worldwide, an increasing number of people are affected by cancer. In 2018, 18.1 million people were diagnosed with new cancer with a mortality rate of 9.6 million (53%). Breast Cancer is on...
Eligibility Criteria
Inclusion
- Postmenopausal women
- Age 50-70 years
- Danish speaking
- Diagnosed with EBC, stage I-III
- Eligible to receive (neo-) adjuvant chemotherapy or adjuvant treatments
- Access to an E-mail address
- Access to smart mobile electronic devices connected to the internet
- Willingness to have the app installed on the smart mobile electronic devices
- Ability to work with the app
Exclusion
- Prior malignancy
- Pre-existing type 2 diabetes or other metabolic diseases
- Withdrawn or not given a consent form
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05280288
Start Date
May 1 2022
End Date
October 1 2025
Last Update
March 15 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.